NCT06991491View on ClinicalTrials.gov

Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions

Pancreatic Cancer

Interventions

COMBINATION_PRODUCT

GnP in combination with Ivonescimab and SBRT

Gemcitabine 1000mg/m2, ivgtt,vdays 1 and 8, nab-Paclitaxel 125mg/m2, ivgtt, days 1 and 8 in combination with Ivonescimab 20mg/kg d1, every 21 days. Cycle 2 will be synchronized with primary or metastatic SBRT.

All Listed Sponsors

lead

West China Hospital

OTHER